Kaken Gets Aadi, whose assets from China

（the article has been updated to make it concise and cohesive)

Kaken Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, has announced its acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million on December 19.

The deal includes Aadi’s leading antibody-drug conjugates (ADCs), two of which have originated from Hangzhou DAC and WuXi Biologics. These programs are currently in clinical development in China.

While Aadi is not a new company, it represents a fresh model for Chinese developers aiming to globalize their innovations. This acquisition marks a significant step in the expansion of Chinese biotech assets onto the global stage.

2024 Breakthrough of the Year: Lenacapavir
Science magazine has named Lenacapavir the 2024 Breakthrough of the Year, highlighting its efficacy in preventing HIV infections. Approved by the U.S. FDA for multi-strain HIV treatment, the drug is hailed as a pivotal advancement in the fight against HIV/AIDS. In clinical trials Purpose1 and Purpose2, early results showed 100% efficacy, with no cases of HIV infection among women who had received the drug since August 2021, according to Gilead Sciences and NPR.

Astellas Presents Pre-clinical Data for Obesity Drug ASC47
Astellas, Japan’s second-largest pharmaceutical company, has revealed promising pre-clinical data for ASC47, a muscle-preserving weight loss drug candidate. When used in combination with semaglutide, ASC47 demonstrated superior weight loss results compared to semaglutide monotherapy, according to a company press release.